These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 20937940)

  • 1. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy.
    Miravalle A; Jensen R; Kinkel RP
    Arch Neurol; 2011 Feb; 68(2):186-91. PubMed ID: 20937940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis.
    Schröder A; Lee DH; Hellwig K; Lukas C; Linker RA; Gold R
    Arch Neurol; 2010 Nov; 67(11):1391-4. PubMed ID: 20625069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?
    Lenhard T; Biller A; Mueller W; Metz I; Schönberger J; Wildemann B
    Neurology; 2010 Aug; 75(9):831-3. PubMed ID: 20805529
    [No Abstract]   [Full Text] [Related]  

  • 4. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.
    Balcer LJ; Galetta SL; Calabresi PA; Confavreux C; Giovannoni G; Havrdova E; Hutchinson M; Kappos L; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA
    Neurology; 2007 Apr; 68(16):1299-304. PubMed ID: 17438220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis.
    Rinaldi F; Perini P; Calabrese M; Rinaldi L; Gallo P
    Mult Scler; 2009 Nov; 15(11):1359-62. PubMed ID: 19812116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.
    Calabresi PA; Giovannoni G; Confavreux C; Galetta SL; Havrdova E; Hutchinson M; Kappos L; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Lublin FD; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
    Neurology; 2007 Oct; 69(14):1391-403. PubMed ID: 17761550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab dosage suspension: are we helping or hurting?
    West TW; Cree BA
    Ann Neurol; 2010 Sep; 68(3):395-9. PubMed ID: 20818793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.
    Wenning W; Haghikia A; Laubenberger J; Clifford DB; Behrens PF; Chan A; Gold R
    N Engl J Med; 2009 Sep; 361(11):1075-80. PubMed ID: 19741228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple sclerosis associated fatigue during natalizumab treatment.
    Putzki N; Yaldizli O; Tettenborn B; Diener HC
    J Neurol Sci; 2009 Oct; 285(1-2):109-13. PubMed ID: 19560168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressive multifocal leukoencephalopathy after natalizumab monotherapy.
    Lindå H; von Heijne A; Major EO; Ryschkewitsch C; Berg J; Olsson T; Martin C
    N Engl J Med; 2009 Sep; 361(11):1081-7. PubMed ID: 19741229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients.
    Vellinga MM; Castelijns JA; Barkhof F; Uitdehaag BM; Polman CH
    Neurology; 2008 Mar; 70(13 Pt 2):1150-1. PubMed ID: 17872364
    [No Abstract]   [Full Text] [Related]  

  • 12. Observations during an elective interruption of natalizumab treatment: a post-marketing study.
    Borriello G; Prosperini L; Marinelli F; Fubelli F; Pozzilli C
    Mult Scler; 2011 Mar; 17(3):372-5. PubMed ID: 21148264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
    Rudick RA; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Radue EW; Lublin FD; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA; Sandrock AW;
    N Engl J Med; 2006 Mar; 354(9):911-23. PubMed ID: 16510745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
    Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG
    Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.
    Langer-Gould A; Atlas SW; Green AJ; Bollen AW; Pelletier D
    N Engl J Med; 2005 Jul; 353(4):375-81. PubMed ID: 15947078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Update on current care guidelines: diagnostics, treatment and rehabilitation of multiple sclerosis].
    Elovaara I; Atula S; Erälinna JP; Färkkilä M; Pirttilä T; Remes A; Ruutiainen J; Varis T; ;
    Duodecim; 2010; 126(2):199-200. PubMed ID: 20405605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical, radiographic, prognostic and therapeutic aspects of demelinating disease with tumefactive demyelinating lesions].
    Launay M; Lebrun C; Giordana E; Chanalet S; Thomas P
    Rev Neurol (Paris); 2011 Jan; 167(1):14-22. PubMed ID: 20739040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy.
    Berger JR
    Mult Scler; 2008 Jun; 14(5):708-10. PubMed ID: 18566035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.
    Comi G; Cohen JA; Arnold DL; Wynn D; Filippi M;
    Ann Neurol; 2011 Jan; 69(1):75-82. PubMed ID: 21280077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.
    Kleinschmidt-DeMasters BK; Miravalle A; Schowinsky J; Corboy J; Vollmer T
    J Neuropathol Exp Neurol; 2012 Jul; 71(7):604-17. PubMed ID: 22710964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.